{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T13:18:38Z","timestamp":1740143918618,"version":"3.37.3"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2021,3,8]],"date-time":"2021-03-08T00:00:00Z","timestamp":1615161600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,3,8]],"date-time":"2021-03-08T00:00:00Z","timestamp":1615161600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Res Cardiol"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1007\/s00392-021-01830-1","type":"journal-article","created":{"date-parts":[[2021,3,8]],"date-time":"2021-03-08T17:03:43Z","timestamp":1615223023000},"page":"1554-1563","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Heart failure re-hospitalizations and subsequent fatal events in coronary artery disease: insights from COMMANDER-HF, EPHESUS, and EXAMINE"],"prefix":"10.1007","volume":"110","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2304-6138","authenticated-orcid":false,"given":"Jo\u00e3o Pedro","family":"Ferreira","sequence":"first","affiliation":[]},{"given":"John G.","family":"Cleland","sequence":"additional","affiliation":[]},{"given":"Carolyn S. P.","family":"Lam","sequence":"additional","affiliation":[]},{"given":"Stefan D.","family":"Anker","sequence":"additional","affiliation":[]},{"given":"Mandeep R.","family":"Mehra","sequence":"additional","affiliation":[]},{"given":"Dirk J.","family":"van Veldhuisen","sequence":"additional","affiliation":[]},{"given":"William M.","family":"Byra","sequence":"additional","affiliation":[]},{"given":"David A.","family":"La Police","sequence":"additional","affiliation":[]},{"given":"Bertram","family":"Pitt","sequence":"additional","affiliation":[]},{"given":"Barry","family":"Greenberg","sequence":"additional","affiliation":[]},{"given":"Faiez","family":"Zannad","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2021,3,8]]},"reference":[{"key":"1830_CR1","doi-asserted-by":"publisher","first-page":"d8059","DOI":"10.1136\/bmj.d8059","volume":"344","author":"K Smolina","year":"2012","unstructured":"Smolina K, Wright FL, Rayner M, Goldacre MJ (2012) Determinants of the decline in mortality from acute myocardial infarction in England between 2002 and 2010: linked national database study. BMJ 344:d8059","journal-title":"BMJ"},{"key":"1830_CR2","doi-asserted-by":"publisher","first-page":"d8136","DOI":"10.1136\/bmj.d8136","volume":"344","author":"P Bandosz","year":"2012","unstructured":"Bandosz P, O\u2019Flaherty M, Drygas W, Rutkowski M, Koziarek J, Wyrzykowski B, Bennett K, Zdrojewski T, Capewell S (2012) Decline in mortality from coronary heart disease in Poland after socioeconomic transformation: modelling study. BMJ 344:d8136","journal-title":"BMJ"},{"key":"1830_CR3","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/S0140-6736(17)32520-5","volume":"391","author":"N Conrad","year":"2017","unstructured":"Conrad N, Judge A, Tran J, Mohseni H, Hedgecott D, Crespillo AP, Allison M, Hemingway H, Cleland JG, McMurray JJV, Rahimi K (2017) Temporal trends and patterns in heart failure incidence: a population-based study of 4 million individuals. Lancet 391:572\u2013580","journal-title":"Lancet"},{"key":"1830_CR4","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1001\/jamacardio.2019.3593","volume":"4","author":"N Conrad","year":"2019","unstructured":"Conrad N, Judge A, Canoy D, Tran J, Pinho-Gomes AC, Millett ERC, Salimi-Khorshidi G, Cleland JG, McMurray JJV, Rahimi K (2019) Temporal trends and patterns in mortality after incident heart failure: a longitudinal analysis of 86000 individuals. JAMA Cardiol 4:1102\u20131111","journal-title":"JAMA Cardiol"},{"key":"1830_CR5","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.ejim.2019.10.017","volume":"71","author":"M Kobayashi","year":"2020","unstructured":"Kobayashi M, Voors AA, Girerd N, Billotte M, Anker SD, Cleland JG, Lang CC, Ng LL, van Veldhuisen DJ, Dickstein K, Metra M, Duarte K, Rossignol P, Zannad F, Ferreira JP (2020) Heart failure etiologies and clinical factors precipitating for worsening heart failure: findings from BIOSTAT-CHF. Eur J Intern Med 71:62\u201369","journal-title":"Eur J Intern Med"},{"issue":"2","key":"1830_CR6","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1002\/ejhf.682","volume":"19","author":"M Arrigo","year":"2017","unstructured":"Arrigo M, Gayat E, Parenica J, Ishihara S, Zhang J, Choi DJ, Park JJ, Alhabib KF, Sato N, Miro O, Maggioni AP, Zhang Y, Spinar J, Cohen-Solal A, Iwashyna TJ, Mebazaa A (2017) Precipitating factors and 90-day outcome of acute heart failure: a report from the intercontinental GREAT registry. Eur J Heart Fail 19(2):201\u2013208","journal-title":"Eur J Heart Fail"},{"key":"1830_CR7","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1056\/NEJMoa1808848","volume":"379","author":"F Zannad","year":"2018","unstructured":"Zannad F, Anker SD, Byra WM, Cleland JGF, Fu M, Gheorghiade M, Lam CSP, Mehra MR, Neaton JD, Nessel CC, Spiro TE, van Veldhuisen DJ, Greenberg B (2018) Rivaroxaban in patients with heart failure, sinus rhythm, and coronary disease. N Engl J Med 379:1332\u20131342","journal-title":"N Engl J Med"},{"issue":"44","key":"1830_CR8","doi-asserted-by":"publisher","first-page":"3593","DOI":"10.1093\/eurheartj\/ehz427","volume":"40","author":"MR Mehra","year":"2019","unstructured":"Mehra MR, Vaduganathan M, Fu M, Ferreira JP, Anker SD, Cleland JGF, Lam CSP, van Veldhuisen DJ, Byra WM, Spiro TE, Deng H, Zannad F, Greenberg B (2019) A comprehensive analysis of the effects of rivaroxaban on stroke or transient ischaemic attack in patients with heart failure, coronary artery disease, and sinus rhythm: the COMMANDER HF trial. Eur Heart J 40(44):3593\u20133602","journal-title":"Eur Heart J"},{"issue":"6","key":"1830_CR9","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1001\/jamacardio.2019.1049","volume":"4","author":"B Greenberg","year":"2019","unstructured":"Greenberg B, Neaton JD, Anker SD, Byra WM, Cleland JGF, Deng H, Fu M, La Police DA, Lam CSP, Mehra MR, Nessel CC, Spiro TE, van Veldhuisen DJ, Vanden Boom CM, Zannad F (2019) Association of rivaroxaban with thromboembolic events in patients with heart failure, coronary disease, and sinus rhythm: a post hoc analysis of the COMMANDER HF trial. JAMA Cardiol 4(6):515\u2013523","journal-title":"JAMA Cardiol"},{"issue":"7","key":"1830_CR10","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1161\/CIRCULATIONAHA.119.041523","volume":"140","author":"JGF Cleland","year":"2019","unstructured":"Cleland JGF, Pellicori P (2019) Myocardial dysfunction and coronary artery disease as therapeutic targets in heart failure. Circulation 140(7):538\u2013541","journal-title":"Circulation"},{"issue":"1","key":"1830_CR11","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1023\/A:1011119003788","volume":"15","author":"B Pitt","year":"2001","unstructured":"Pitt B, Williams G, Remme W, Martinez F, Lopez-Sendon J, Zannad F, Neaton J, Roniker B, Hurley S, Burns D, Bittman R, Kleiman J (2001) The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone post-AMI heart failure efficacy and survival study. Cardiovasc Drugs Ther 15(1):79\u201387","journal-title":"Cardiovasc Drugs Ther"},{"issue":"14","key":"1830_CR12","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1056\/NEJMoa1305889","volume":"369","author":"WB White","year":"2013","unstructured":"White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, Perez AT, Fleck PR, Mehta CR, Kupfer S, Wilson C, Cushman WC, Zannad F (2013) Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 369(14):1327\u20131335","journal-title":"N Engl J Med"},{"issue":"7","key":"1830_CR13","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1002\/ejhf.266","volume":"17","author":"F Zannad","year":"2015","unstructured":"Zannad F, Greenberg B, Cleland JG, Gheorghiade M, van Veldhuisen DJ, Mehra MR, Anker SD, Byra WM, Fu M, Mills RM (2015) Rationale and design of a randomized, double-blind, event-driven, multicentre study comparing the efficacy and safety of oral rivaroxaban with placebo for reducing the risk of death, myocardial infarction or stroke in subjects with heart failure and significant coronary artery disease following an exacerbation of heart failure: the COMMANDER HF trial. Eur J Heart Fail 17(7):735\u2013742","journal-title":"Eur J Heart Fail"},{"issue":"4","key":"1830_CR14","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/j.ahj.2011.08.004","volume":"162","author":"WB White","year":"2011","unstructured":"White WB, Bakris GL, Bergenstal RM, Cannon CP, Cushman WC, Fleck P, Heller S, Mehta C, Nissen SE, Perez A, Wilson C, Zannad F (2011) EXamination of cArdiovascular outcoMes with alogliptIN versus standard of carE in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE): a cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes with acute coronary syndrome. Am Heart J 162(4):620-626.e1","journal-title":"Am Heart J"},{"key":"1830_CR15","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.ahj.2019.08.019","volume":"218","author":"JP Ferreira","year":"2019","unstructured":"Ferreira JP, Rossignol P, Dewan P, Lamiral Z, White WB, Pitt B, McMurray JJV, Zannad F (2019) Income level and inequality as complement to geographical differences in cardiovascular trials. Am Heart J 218:66\u201374","journal-title":"Am Heart J"},{"issue":"5","key":"1830_CR16","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1016\/j.ijcard.2012.12.018","volume":"167","author":"F Zannad","year":"2013","unstructured":"Zannad F, Stough WG, Regnault V, Gheorghiade M, Deliargyris E, Gibson CM, Agewall S, Berkowitz SD, Burton P, Calvo G, Goldstein S, Verheugt FW, Koglin J, O\u2019Connor CM (2013) Is thrombosis a contributor to heart failure pathophysiology? Possible mechanisms, therapeutic opportunities, and clinical investigation challenges. Int J Cardiol 167(5):1772\u20131782","journal-title":"Int J Cardiol"},{"key":"1830_CR17","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1093\/eurheartj\/ehw213","volume":"37","author":"JP Ferreira","year":"2016","unstructured":"Ferreira JP, Girerd N, Alshalash S, Konstam MA, Zannad F (2016) Antithrombotic therapy in heart failure patients with and without atrial fibrillation: update and future challenges. Eur Heart J 37:2455\u20132464","journal-title":"Eur Heart J"},{"issue":"7","key":"1830_CR18","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/j.jacc.2017.12.011","volume":"71","author":"JP Ferreira","year":"2018","unstructured":"Ferreira JP, Girerd N, Gregson J, Latar I, Sharma A, Pfeffer MA, McMurray JJV, Abdul-Rahim AH, Pitt B, Dickstein K, Rossignol P, Zannad F (2018) Stroke risk in patients with reduced ejection fraction after myocardial infarction without atrial fibrillation. J Am Coll Cardiol 71(7):727\u2013735","journal-title":"J Am Coll Cardiol"},{"issue":"36","key":"1830_CR19","doi-asserted-by":"publisher","first-page":"2463","DOI":"10.1093\/eurheartj\/ehv295","volume":"36","author":"PS Jhund","year":"2015","unstructured":"Jhund PS, McMurray JJ, Chaturvedi N, Brunel P, Desai AS, Finn PV, Haffner SM, Solomon SD, Weinrauch LA, Claggett BL, Pfeffer MA (2015) Mortality following a cardiovascular or renal event in patients with type 2 diabetes in the ALTITUDE trial. Eur Heart J 36(36):2463\u20132469","journal-title":"Eur Heart J"},{"key":"1830_CR20","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(20)30748-0","volume":"396","author":"M Vaduganathan","year":"2020","unstructured":"Vaduganathan M (2020) Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials. Lancet 396:121\u2013128","journal-title":"Lancet"},{"key":"1830_CR21","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1002\/ejhf.1585","volume":"21","author":"J Tromp","year":"2020","unstructured":"Tromp J, Ferreira JP, Janwanishstaporn S, Shah M, Greenberg B, Zannad F, Lam CSP (2020) Heart failure around the world. Eur J Heart Fail 21:1187\u20131196","journal-title":"Eur J Heart Fail"},{"issue":"19","key":"1830_CR22","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.1016\/j.jacc.2019.02.015","volume":"73","author":"SJ Greene","year":"2019","unstructured":"Greene SJ, Fonarow GC, DeVore AD, Sharma PP, Vaduganathan M, Albert NM, Duffy CI, Hill CL, McCague K, Patterson JH, Spertus JA, Thomas L, Williams FB, Hernandez AF, Butler J (2019) Titration of medical therapy for heart failure with reduced ejection fraction. J Am Coll Cardiol 73(19):2365\u20132383","journal-title":"J Am Coll Cardiol"},{"key":"1830_CR23","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1056\/NEJMoa1915928","volume":"382","author":"PW Armstrong","year":"2020","unstructured":"Armstrong PW, Pieske B, Anstrom KJ, Ezekowitz J, Hernandez AF, Butler J, Lam CSP, Ponikowski P, Voors AA, Jia G, McNulty SE, Patel MJ, Roessig L, Koglin J, O\u2019Connor CM (2020) Vericiguat in patients with heart failure and reduced ejection fraction. N Engl J Med 382:1883\u20131893","journal-title":"N Engl J Med"},{"key":"1830_CR24","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, Belohlavek J, Bohm M, Chiang CE, Chopra VK, de Boer RA, Desai AS, Diez M, Drozdz J, Dukat A, Ge J, Howlett JG, Katova T, Kitakaze M, Ljungman CEA, Merkely B, Nicolau JC, O\u2019Meara E, Petrie MC, Vinh PN, Schou M, Tereshchenko S, Verma S, Held C, DeMets DL, Docherty KF, Jhund PS, Bengtsson O, Sjostrand M, Langkilde AM (2019) Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 381:1995\u20132008","journal-title":"N Engl J Med"},{"issue":"11","key":"1830_CR25","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","volume":"371","author":"JJ McMurray","year":"2014","unstructured":"McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR (2014) Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371(11):993\u20131004","journal-title":"N Engl J Med"},{"issue":"6","key":"1830_CR26","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1056\/NEJMoa1812851","volume":"380","author":"EJ Velazquez","year":"2019","unstructured":"Velazquez EJ, Morrow DA, DeVore AD, Duffy CI, Ambrosy AP, McCague K, Rocha R, Braunwald E (2019) Angiotensin-neprilysin inhibition in acute decompensated heart failure. N Engl J Med 380(6):539\u2013548","journal-title":"N Engl J Med"},{"issue":"7","key":"1830_CR27","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1161\/CIRCULATIONAHA.119.039609","volume":"140","author":"KR Branch","year":"2019","unstructured":"Branch KR, Probstfield JL, Eikelboom JW, Bosch J, Maggioni AP, Cheng RK, Bhatt DL, Avezum A, Fox KAA, Connolly SJ, Shestakovska O, Yusuf S (2019) Rivaroxaban with or without aspirin in patients with heart failure and chronic coronary or peripheral artery disease. Circulation 140(7):529\u2013537","journal-title":"Circulation"},{"key":"1830_CR28","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","volume":"377","author":"JW Eikelboom","year":"2017","unstructured":"Eikelboom JW, Connolly SJ, Bosch J, Dagenais GR, Hart RG, Shestakovska O, Diaz R, Alings M, Lonn EM, Anand SS, Widimsky P, Hori M, Avezum A, Piegas LS, Branch KRH, Probstfield J, Bhatt DL, Zhu J, Liang Y, Maggioni AP, Lopez-Jaramillo P, O\u2019Donnell M, Kakkar A, Fox KAA, Parkhomenko AN, Ertl G, Stork S, Keltai M, Ryden L, Pogosova N, Dans AL, Lanas F, Commerford PJ, Torp-Pedersen C, Guzik TJ, Verhamme PB, Vinereanu D, Kim JH, Tonkin AM, Lewis BS, Felix C, Yusoff K, Steg PG, Metsarinne KP, Cook Bruns N, Misselwitz F, Chen E, Leong D, Yusuf S (2017) Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med 377:1319\u20131330","journal-title":"N Engl J Med"},{"key":"1830_CR29","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/S0140-6736(17)32873-8","volume":"391","author":"F Zannad","year":"2017","unstructured":"Zannad F (2017) Rising incidence of heart failure demands action. Lancet 391:518\u2013519","journal-title":"Lancet"}],"container-title":["Clinical Research in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-021-01830-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00392-021-01830-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-021-01830-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,30]],"date-time":"2021-09-30T08:24:24Z","timestamp":1632990264000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00392-021-01830-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,8]]},"references-count":29,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["1830"],"URL":"https:\/\/doi.org\/10.1007\/s00392-021-01830-1","relation":{},"ISSN":["1861-0684","1861-0692"],"issn-type":[{"type":"print","value":"1861-0684"},{"type":"electronic","value":"1861-0692"}],"subject":[],"published":{"date-parts":[[2021,3,8]]},"assertion":[{"value":"3 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr Ferreira is a consultant for Boehringer-Ingelheim. Dr Zannad reports steering committee personal fees from Applied Therapeutics, Amgen, Bayer, Boehringer, Novartis, Janssen, Cellprothera and CVRx, advisory board personal fees from, AstraZeneca, Vifor Fresenius, Cardior, Cereno pharmaceutical, Corvidia, Merck, Myokardia, NovoNordisk and Owkin, stock options at Cereno and G3Pharmaceutical, and being the founder of the Global Cardiovascular Clinical Trialist Forum. Dr Lam has received research support from Boston Scientific, Bayer, Roche Diagnostics, AstraZeneca, Medtronic, and Vifor Pharma; has served as consultant or on the Advisory Board\/ Steering Committee\/ Executive Committee for Abbott Diagnostics, Amgen, Applied Therapeutics, AstraZeneca, Bayer, Biofourmis, Boehringer Ingelheim, Boston Scientific, Corvia Medical, Cytokinetics, Darma Inc., Us2.ai, JanaCare, Janssen Research & Development LLC, Medtronic, Menarini Group, Merck, MyoKardia, Novartis, Novo Nordisk, Radcliffe Group Ltd., Roche Diagnostics, Sanofi, Stealth BioTherapeutics, The Corpus, Vifor Pharma and WebMD Global LLC; and serves as co-founder & non-executive director of Us2.ai. Dr Greenberg reports consulting fees from Amgen, Cytokinetics, EBR Systems, Impulse Dynamics, Ionis, Jaan, Janssen, Merck, Myokardia, Sanofi, Vifor, Viking, Windtree and Zensun. All the other authors report not having relevant conflicts of interest regarding the content of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}